CorMedix Inc. filed soliciting material under Schedule 14A (DFAN14A) on November 16, 2026, in connection with its proposed acquisition of substantially all of the assets of Heron Therapeutics and its third quarter 2026 earnings disclosures.
CorMedix Inc. filed a Form 8-K on November 16, 2026, furnishing the transcript of its investor conference call held on November 12, 2026, which discussed financial results for the quarter ended September 30, 2026, and also disclosed details related to a proposed acquisition of …
Vir Biotechnology, Inc. filed a Form 8-K on November 13, 2026, disclosing an underwriting agreement dated November 12, 2026, for a public offering of 15,000,000 shares of common stock at $10.00 per share, with an expected closing date of November 16, 2026.
Powerus Corporation filed a Form 8-K on November 13, 2026, disclosing historical and pro forma financial statements for Autonomous Power Corporation ("Legacy Powerus") following the merger completed on October 1, 2026.
KALA BIO, Inc. filed a Form 8-K on November 16, 2026, disclosing that a Nasdaq Hearings Panel granted the company a conditional extension to maintain its listing on The Nasdaq Capital Market following a minimum bid price deficiency notification received on August 27, 2026.
DataMEDS AI, Inc. filed a Form 8-K on November 16, 2026, disclosing its entry into an at-the-market sales agreement with Dawson James Securities, Inc. to offer and sell shares of its common stock from time to time on The Nasdaq Capital Market.
Income Opportunity Realty Investors, Inc. filed an 8-K with the Securities and Exchange Commission on November 13, 2026, disclosing the voting results from its Annual Meeting of Stockholders held on November 11, 2026.
Aclaris Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis did not achieve its primary endpoint, while also announcing the initiation of a new Phase 2b trial and additional …
Rezolute, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing an underwriting agreement dated November 13, 2026, covering an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $93.5 million in net proceeds.
Oscar Health, Inc. filed a Form 8-K on November 16, 2026, disclosing the appointment of three new independent directors to its Board of Directors, effective November 13, 2026, expanding the board from eight to eleven members.